Clinical Trials Logo

Lung Cancer Metastatic clinical trials

View clinical trials related to Lung Cancer Metastatic.

Filter by:

NCT ID: NCT04311762 Recruiting - Clinical trials for Lung Cancer Metastatic

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

Start date: February 26, 2020
Phase: Phase 1
Study type: Interventional

The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.

NCT ID: NCT04085315 Recruiting - EGFR Gene Mutation Clinical Trials

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Start date: November 12, 2019
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and/or bad, it has on EGFR-mutated lung cancer.

NCT ID: NCT03706287 Recruiting - Clinical trials for Lung Cancer Metastatic

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Start date: December 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2(VEGFR)、FGFR(fibroblast growth factor receptor), platelet-derived growth factor receptor(PDGFR) and tumor cell proliferation related kinase c-Kit, combined with platinum plus pemetrexed in T790M mutation negative metastatic non-squamous non-small cell lung cancer(NSCLC) after the failure of EGFR-TKI.

NCT ID: NCT03693339 Recruiting - Cancer Clinical Trials

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.

NCT ID: NCT03693326 Recruiting - Cancer Clinical Trials

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.

NCT ID: NCT03543306 Recruiting - Cancer Clinical Trials

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Start date: June 30, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event.

NCT ID: NCT02976740 Recruiting - Clinical trials for Lung Cancer Metastatic

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the treatment of stage IV NSCLC patients who failed in second-line chemotherapy.